// App-Quantinova.ai

OP0139 : FUNCTIONAL EVALUATION OF THE SJÖGREN’S SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS DDX6-CXCR5 RISK INTERVAL

Researchers

Presenter

  • M. M. Wiley

Principal Investigators

  • K. L. Tessneer

  • M. L. Joachims

  • A. M. Stolarczyk

  • A. Rasmussen

  • S. J. Bowman

  • L. Radfar

  • R. Omdal

  • M. Wahren-Herlenius

  • B. M. Warner

  • T. Witte

  • R. Jonsson

  • M. Rischmueller

  • P. M. Gaffney

  • J. A. James

  • L. Ronnblom

  • R. H. Scofield

  • X. Mariette

  • W. F. Ng

  • K. L. Sivils

  • G. Nordmark

  • B. Tsao

  • C. Lessard

Medical Centers

  • Oklahoma Medical Research Foundation, Oklahoma City, United States

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • University of Oklahoma,Oklahoma City,Verenigde Staten

  • University of Bergen, Bergen, Norway

  • Karolinska Institutet, Stockholm, Sweden

  • National Institute of Dental and Craniofacial Research (NIDCR), NIH, Bethesda, MD, United States of America

  • Hannover Medical School, Hannover, Germany

  • Haukeland University Hospital, Bergen, Norway

  • University of Adelaide, Adelaide, Australia

  • Uppsala University Hospital, Uppsala, Sweden

  • Universite Paris-Sud, Le Kremlin Bictre, France

  • NHR Biomedical Research Centre, Newcastle Upon Tyne, United Kingdom

  • Medical University of South Carolina, Charleston, United States of America

Locations

  • United States

  • United Kingdom

  • Norway

  • Sweden

  • Germany

  • Australia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

  • Sjogren's syndrome

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Progentec Diagnostics, Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved